Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by Carbovir-triphosphate

A S Ray; K S Anderson

doi:10.1081/NCN-100002528

Mechanistic studies to understand the inhibition of wild type and mutant HIV-1 reverse transcriptase by Carbovir-triphosphate

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1247-50. doi: 10.1081/NCN-100002528.

Authors

A S Ray¹, K S Anderson

Affiliation

¹ Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520-8066, USA.

PMID: 11562995
DOI: 10.1081/NCN-100002528

Abstract

Abacavir (1592U89) has recently been approved by the FDA for treatment of HIV infection. Transient kinetic studies were carried out to better understand the interaction of the active metabolite of Abacavir (Carbovir-triphosphate) with wild type and mutant HIV-1 reverse transcriptase. Some of the data is summarized and used as a basis for discussion of inhibition by CBVTP and previously studied nucleoside analogs.

MeSH terms

Anti-HIV Agents / pharmacology*
DNA Primers / chemistry
DNA Primers / metabolism
Deoxyguanine Nucleotides / pharmacology*
HIV Reverse Transcriptase / antagonists & inhibitors*
HIV Reverse Transcriptase / chemistry
HIV Reverse Transcriptase / metabolism
RNA / chemistry
RNA / metabolism
Reverse Transcriptase Inhibitors / pharmacology*
Templates, Genetic

Substances

Anti-HIV Agents
DNA Primers
Deoxyguanine Nucleotides
RNA primers
Reverse Transcriptase Inhibitors
carbovir triphosphate
RNA
HIV Reverse Transcriptase